estrone has been researched along with Neoplasm Metastasis in 33 studies
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.
Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The conversion of 1 beta [3H] androstenedione to estrone in the presence of NADPH by breast cancer homogenates was assessed in tumors from 35 subjects together with estrogen and progesterone receptor concentration." | 7.67 | Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance. ( Bezwoda, WR; Dansey, R; Esser, JD; Mansoor, N, 1987) |
| "Postmenopausal women with metastatic breast cancer were treated with trilostane, initially 240 mg daily increasing after 3 days to 480 mg daily and after a further three days to 960 mg daily." | 7.67 | Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. ( Beardwell, CG; Bu'lock, D; Hindley, AC; St John, J; Wilkinson, PM, 1985) |
| "Fifty-nine postmenopausal women with advanced breast cancer were treated with tamoxifen (antiestrogen), 20 mg orally twice a day for at least 2 months." | 7.65 | Tamoxifen (antiestrogen) therapy in advanced breast cancer. ( Kennedy, BJ; Kiang, DT, 1977) |
| "40), but not for MPA and estrone, indicating better adrenal suppression by higher MPA dosage and plasma levels." | 6.66 | Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. ( Doorenbos, H; Sleijfer, DT; Sluiter, WJ; van Veelen, H; Willemse, PH, 1985) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 6.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Treatment with estrone, but not 17β-estradiol, and HSD17B14 overexpression both stimulate an EMT, matrigel invasion, and lung, bone, and liver metastasis in estrogen-receptor-positive (ER+) breast cancer models, while HSD17B14 knockdown reverses the EMT." | 5.72 | Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis. ( Diaz-Ruano, AB; Ince, TA; Nunes de Paiva, V; Picon-Ruiz, M; Qureshi, R; Sho, M; Slingerland, J; Van Booven, D, 2022) |
| "We conducted a pilot study assessing the effects of the selective estrogen receptor modulator, tamoxifen, on the pharmacokinetics, pharmacodynamics, and safety of the steroidal, irreversible aromatase inhibitor (AI), exemestane, when the two were coadministered in postmenopausal women with metastatic breast cancer." | 5.11 | Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. ( Asnis, AG; Duncan, B; Francis, D; Hortobagyi, GN; Rivera, E; Schaaf, LJ; Valero, V, 2004) |
| "The conversion of 1 beta [3H] androstenedione to estrone in the presence of NADPH by breast cancer homogenates was assessed in tumors from 35 subjects together with estrogen and progesterone receptor concentration." | 3.67 | Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance. ( Bezwoda, WR; Dansey, R; Esser, JD; Mansoor, N, 1987) |
| "Postmenopausal women with metastatic breast cancer were treated with trilostane, initially 240 mg daily increasing after 3 days to 480 mg daily and after a further three days to 960 mg daily." | 3.67 | Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. ( Beardwell, CG; Bu'lock, D; Hindley, AC; St John, J; Wilkinson, PM, 1985) |
| "Fifty-nine postmenopausal women with advanced breast cancer were treated with tamoxifen (antiestrogen), 20 mg orally twice a day for at least 2 months." | 3.65 | Tamoxifen (antiestrogen) therapy in advanced breast cancer. ( Kennedy, BJ; Kiang, DT, 1977) |
| " STX64 was administered orally (nine patients at 5 mg and five patients at 20 mg) as an initial dose followed 1 week later by 3 x 2 weekly cycles, with each cycle comprising daily dosing for 5 days followed by 9 days off treatment." | 2.72 | Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. ( Coombes, RC; Dobbs, N; Elliott, M; Kulinskaya, E; Potter, BV; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Sufi, S; Vigushin, D; Ward, R; Wilson, RH; Woo, LW, 2006) |
| "40), but not for MPA and estrone, indicating better adrenal suppression by higher MPA dosage and plasma levels." | 2.66 | Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer. ( Doorenbos, H; Sleijfer, DT; Sluiter, WJ; van Veelen, H; Willemse, PH, 1985) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 2.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "Treatment with estrone, but not 17β-estradiol, and HSD17B14 overexpression both stimulate an EMT, matrigel invasion, and lung, bone, and liver metastasis in estrogen-receptor-positive (ER+) breast cancer models, while HSD17B14 knockdown reverses the EMT." | 1.72 | Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis. ( Diaz-Ruano, AB; Ince, TA; Nunes de Paiva, V; Picon-Ruiz, M; Qureshi, R; Sho, M; Slingerland, J; Van Booven, D, 2022) |
| "Liver metastases of hormone-dependent adrenal carcinomas continued growth and could not be influenced by removal of estrogen, although the primary transplant regressed." | 1.26 | Hormonal control of growth and progression in tumors of Nb rats and a theory of action. ( Noble, RL, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (81.82) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 3 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Qureshi, R | 3 |
| Picon-Ruiz, M | 3 |
| Sho, M | 3 |
| Van Booven, D | 3 |
| Nunes de Paiva, V | 3 |
| Diaz-Ruano, AB | 3 |
| Ince, TA | 3 |
| Slingerland, J | 3 |
| NISSEN-MEYER, R | 1 |
| ROBERTSON, DM | 1 |
| WILLIAMS, DC | 1 |
| WOTIZ, HH | 1 |
| STEWART, WK | 1 |
| FLEMING, LW | 1 |
| CUTTS, JH | 1 |
| NOBLE, RL | 2 |
| ADAMS, JB | 1 |
| KRANT, MJ | 1 |
| Rivera, E | 1 |
| Valero, V | 1 |
| Francis, D | 1 |
| Asnis, AG | 1 |
| Schaaf, LJ | 1 |
| Duncan, B | 1 |
| Hortobagyi, GN | 1 |
| Stanway, SJ | 1 |
| Purohit, A | 1 |
| Woo, LW | 1 |
| Sufi, S | 1 |
| Vigushin, D | 1 |
| Ward, R | 1 |
| Wilson, RH | 1 |
| Stanczyk, FZ | 1 |
| Dobbs, N | 1 |
| Kulinskaya, E | 1 |
| Elliott, M | 1 |
| Potter, BV | 1 |
| Reed, MJ | 1 |
| Coombes, RC | 2 |
| Rothnie, A | 1 |
| Callaghan, R | 1 |
| Deeley, RG | 1 |
| Cole, SP | 1 |
| Stuart-Harris, RC | 1 |
| Smith, IE | 1 |
| Jalůvka, V | 1 |
| Kratzsch, E | 1 |
| Fisher, B | 1 |
| Gunduz, N | 1 |
| Saffer, EA | 1 |
| Johannessen, DC | 1 |
| Engan, T | 1 |
| Di Salle, E | 1 |
| Zurlo, MG | 1 |
| Paolini, J | 1 |
| Ornati, G | 1 |
| Piscitelli, G | 1 |
| Kvinnsland, S | 1 |
| Lonning, PE | 1 |
| Santen, RJ | 2 |
| Veldhuis, J | 1 |
| Samojlik, E | 2 |
| Lipton, A | 2 |
| Harvey, H | 2 |
| Wells, SA | 2 |
| Maeyama, M | 2 |
| Ifuku, M | 1 |
| Nakahara, K | 1 |
| Mori, N | 1 |
| Miyakawa, I | 1 |
| Higashi, S | 1 |
| Ruby, EB | 1 |
| Kendall, J | 1 |
| Kiang, DT | 1 |
| Kennedy, BJ | 1 |
| Tominaga, T | 1 |
| Tei, N | 1 |
| Kitamura, M | 1 |
| Taguchi, T | 1 |
| Azuma, Y | 1 |
| Dowsett, M | 1 |
| Stein, RC | 1 |
| Mehta, A | 1 |
| van Veelen, H | 1 |
| Willemse, PH | 1 |
| Sleijfer, DT | 1 |
| Sluiter, WJ | 1 |
| Doorenbos, H | 1 |
| Bezwoda, WR | 1 |
| Mansoor, N | 1 |
| Dansey, R | 1 |
| Esser, JD | 1 |
| Beardwell, CG | 1 |
| Hindley, AC | 1 |
| Wilkinson, PM | 1 |
| St John, J | 1 |
| Bu'lock, D | 1 |
| Argüelles, AE | 1 |
| Poggi, UL | 1 |
| Saborida, C | 1 |
| Hoffman, C | 1 |
| Chekherdemian, M | 1 |
| Blanchard, O | 1 |
| Dao, TL | 2 |
| Libby, PR | 1 |
| Kirschner, MA | 1 |
| Wider, JA | 1 |
| Ross, GT | 1 |
| Bordiushkov, IuN | 1 |
| Mindlin, SS | 1 |
| Verkhovtseva, AI | 1 |
| Dickey, RP | 1 |
| Minton, JP | 1 |
| Hellman, L | 1 |
| Zumoff, B | 1 |
| Fishman, J | 1 |
| Gallagher, TF | 1 |
| Herzberg, JJ | 1 |
| Potjan, K | 1 |
| Gebauer, D | 1 |
| Morreal, CE | 1 |
3 reviews available for estrone and Neoplasm Metastasis
| Article | Year |
|---|---|
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
[Hormone activity of various Brenner tumors].
Topics: Aged; Breast Neoplasms; Brenner Tumor; Estradiol; Estrone; Female; Humans; Neoplasm Metastasis; Neop | 1982 |
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy | 1977 |
6 trials available for estrone and Neoplasm Metastasis
| Article | Year |
|---|---|
Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy | 2004 |
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androstenediol; Breast Neoplasms; Coumarins; D | 2006 |
Aminoglutethimide in the treatment of advanced breast cancer.
Topics: Adrenalectomy; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; | 1984 |
Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Topics: Aged; Alprostadil; Androgens; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Ne | 1997 |
Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; | 1990 |
Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
Topics: Adrenal Glands; Aged; Androstenedione; Breast Neoplasms; Clinical Trials as Topic; Dehydroepiandrost | 1985 |
25 other studies available for estrone and Neoplasm Metastasis
| Article | Year |
|---|---|
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis.
Topics: 17-Hydroxysteroid Dehydrogenases; Breast Neoplasms; Epithelial-Mesenchymal Transition; Estradiol; Es | 2022 |
ENDOCRINE TREATMENT OF BREAST CANCER.
Topics: Anabolic Agents; Androgens; Breast Neoplasms; Castration; Estrone; Female; Humans; Menopause; Nandro | 1964 |
THE EFFECT OF TRANSPLANTED MAMMARY TUMOURS ON THE CALCIUM BALANCE OF THE RAT.
Topics: Acid Phosphatase; Aging; Alkaline Phosphatase; Animals; Bone and Bones; Bone Marrow; Breast Neoplasm | 1964 |
THE FEMINIZING SYNDROME IN MALE SUBJECTS WITH ADRENOCORTICAL NEOPLASMS.
Topics: 17-Ketosteroids; Adrenal Gland Neoplasms; Adrenogenital Syndrome; Estradiol; Estriol; Estrogens; Est | 1964 |
ESTRONE-INDUCED MAMMARY TUMORS IN THE RAT. I. INDUCTION AND BEHAVIOR OF TUMORS.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinogens; Carcinoma; Estrone; Humans; Lung Neoplasms; | 1964 |
ENZYMIC SYNTHESIS OF STEROID SULFATES. II.
Topics: Adenine Nucleotides; Androsterone; Breast Neoplasms; Cortisone; Dehydroepiandrosterone; Drug Therapy | 1964 |
ESTROGEN HYPEREXCRETION IN A PATIENT WITH NONENDOCRINE CANCER.
Topics: Abdominal Neoplasms; Adrenocortical Hyperfunction; Angiomatosis; Carcinoma; Estradiol; Estriol; Estr | 1965 |
Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1).
Topics: Binding Sites; Biological Transport; Cell Line, Tumor; Estrone; Glutathione; Humans; Hydrolysis; Kin | 2006 |
Interrelation between tumor cell proliferation and 17-fluoresceinated estrone binding following primary tumor removal, radiation, cyclophosphamide, or tamoxifen.
Topics: Animals; Cyclophosphamide; Estrone; Female; Fluorescent Dyes; Immunotherapy; Mammary Neoplasms, Expe | 1983 |
Mechanism of action of aminoglutethimide in breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Breast Neoplasms; Estradiol; Estrogen Antagonists; | 1979 |
Steroidogenesis in cerebral metastatic chorionepithelioma tissue in vitro.
Topics: 17-alpha-Hydroxypregnenolone; Androstenedione; Brain Neoplasms; Choriocarcinoma; Dehydroepiandroster | 1975 |
Urinary steroid excretion in an oophorectomized and adrenalectomized woman in the second trimester of pregnancy.
Topics: 17-Hydroxycorticosteroids; Adrenalectomy; Adrenocorticotropic Hormone; Breast Neoplasms; Castration; | 1975 |
Hormonal control of growth and progression in tumors of Nb rats and a theory of action.
Topics: Adrenal Gland Neoplasms; Animals; Estrogens; Estrone; Female; Kidney Neoplasms; Liver Neoplasms; Mal | 1977 |
Tamoxifen (antiestrogen) therapy in advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Estradiol; Estrone; Female; Humans; Menopause; Middle Aged; Neoplasm | 1977 |
Urinary excretion of steroids and response to oophorectomy in premenopausal women with advanced breast cancer.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adrenal Cortex Hormones; Adult; Breast Neoplasms; Castra | 1975 |
Aromatisation of androstenedione by human breast cancer tissue: correlation with hormone receptor activity and possible biologic significance.
Topics: Androstenedione; Aromatase; Breast Neoplasms; Estrone; Female; Humans; In Vitro Techniques; Menopaus | 1987 |
Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone.
Topics: Adrenal Cortex Hormones; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1985 |
Endocrine profiles and breast cancer.
Topics: 11-Hydroxycorticosteroids; Adult; Aged; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estriol | 1973 |
Conjugation of steroid hormones by breast cancer tissue and selection of patients for adrenalectomy.
Topics: Adrenalectomy; Aged; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Humans; Liver; Li | 1969 |
Leydig cell function in men with gonadotrophin-producing testicular tumors.
Topics: Adult; Choriocarcinoma; Chorionic Gonadotropin; Chromatography, Gas; Dehydroepiandrosterone; Electro | 1970 |
[The mechanism of action of hydrocortisone administered by lumbar puncture in breast cancer].
Topics: 11-Hydroxycorticosteroids; 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Aged; Androsterone; Br | 1973 |
L-Dopa effect on prolactin, follicle-stimulating hormone, and luteinizing hormone in women with advanced breast cancer: a preliminary report.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Bone Neoplasms; Breast Neoplasms; Dihydroxyphenyl | 1972 |
Estradiol metabolism in total extrahepatic biliary obstruction.
Topics: 17-Ketosteroids; Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Cholestasis; Cholesterol; Col | 1970 |
[Hypertrichosis lanuginosa (et terminalis) acquisita as a paraneoplastic syndrome].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Aged; Autopsy; Brain; Estradiol; Estriol; Estrone; Gallb | 1968 |
Isolation and identification of estriol in urine of castrated and adrenalectomized women receiving 4-14C-testosterone.
Topics: Adrenal Glands; Adrenalectomy; Breast Neoplasms; Carbon Isotopes; Castration; Chromatography, Paper; | 1968 |